OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Ip on Remaining Questions With the COVID-19 Vaccine in Oncology

March 23rd 2021

Andrew Ip, MD, MS, discusses remaining questions with the COVID-19 vaccine in patients with cancer.

Dr. Eng Discusses the Ongoing FRESCO-2 Trial in mCRC

March 23rd 2021

Cathy Eng, MD, FACP, FASCO, discusses the ongoing phase 3 FRESCO-2 trial in metastatic colorectal cancer.

Dr. Choti on Challenging Treatment Decisions in NETs

March 23rd 2021

Michael A. Choti, MD, discusses challenging treatment decisions in patients with neuroendocrine tumors.

Dr. Basu-Mallick on the Importance of Clinical Research Examining ctDNA in CRC

March 22nd 2021

Atrayee Basu-Mallick, MD, discusses the importance of clinical research examining the role of circulating tumor DNA in patients with colorectal cancer.

Dr. Longshore on Comprehensive Vs Single-Gene Molecular Testing in Lung Cancer

March 22nd 2021

John Longshore, PhD, FACMG, discusses selecting between comprehensive vs single-gene molecular testing in lung cancer.

Dr. Davies on the Potential Role of Novel BRAF Inhibitors in Melanoma Brain Metastases

March 22nd 2021

Michael A. Davies, MD, PhD, discusses the potential role of novel BRAF inhibitors in treating patients with melanoma and brain metastases.

Dr. Dorff on the Importance of Somatic Testing in mCRPC

March 22nd 2021

Tanya Dorff, MD, discusses the importance of somatic testing in metastatic castration-resistant prostate cancer.

Dr. Hamilton on the Evaluation of Lucitanib/Nivolumab in Gynecologic Cancers

March 22nd 2021

Erika P. Hamilton, MD, discusses the phase 2 LIO-1 trial evaluation of lucitanib and nivolumab across different gynecologic cancer subtypes.

Dr. Herrera on Camidanlumab Tesirine in Relapsed/Refractory Hodgkin Lymphoma

March 19th 2021

Alex Herrera, MD, discusses the potential role of camidanlumab tesirine in patients with relapsed/refractory Hodgkin Lymphoma, which is currently being examined in a phase 2 clinical trial.

Dr. Gibney on the Potential for Fixed-Duration Immunotherapy in Melanoma

March 19th 2021

Geoffrey T. Gibney, MD, discusses the potential utility of fixed-duration immunotherapy in melanoma.

Dr. Trent on the Utility of ctDNA to Understand Primary Mutations in GIST

March 19th 2021

Jonathan C. Trent, MD, PhD, discusses the utility of circulating tumor DNA to understand primary driver mutations in gastrointestinal stromal tumor.

Dr. Kazmi on Tailoring Treatment to Various Subtypes of CRC

March 19th 2021

Syed Kazmi, MD, discusses the importance of tailoring treatment to different subtypes of colorectal cancer.

Dr. Hanna on Approaching Biomarker Testing in Lung Cancer

March 18th 2021

Nasser H. Hanna, MD, discusses his approach to biomarker testing in lung cancer.

Dr. George on Actionable Pathogenic Variants in Adults With Breast or Ovarian Cancers in the Caribbean

March 18th 2021

Sophia George, PhD, discusses actionable pathogenic variants in patients with breast cancer who live in the Caribbean.

Dr. Hurley on Breast Cancer Baseline Characteristics in the Caribbean Vs the United States

March 18th 2021

Judith E. Hurley, MD, discusses the baseline characteristics of patients with breast cancer in the Caribbean vs those in the United States.

Dr. Choueiri on the CheckMate-9ER Exploratory Analysis in Advanced RCC

March 18th 2021

Toni K. Choueiri, MD, discusses results from an exploratory analysis of the phase 3 CheckMate-9ER trial in patients with advanced renal cell carcinoma.

Dr. Levy on the Importance of Testing for KRAS Mutations in Lung Cancer

March 18th 2021

Benjamin P. Levy, MD, discusses the importance of testing for KRAS mutations in lung cancer.

Dr. Martin on Determining Transplant Eligibility in Multiple Myeloma

March 18th 2021

Thomas G. Martin, MD, discusses factors that can inform transplant eligibility in multiple myeloma.

Dr. Salem on the FDA Approval of Y-90 Glass Microspheres for HCC

March 18th 2021

Riad Salem, MD, discusses the FDA approval of TheraSphere™ Yttrium-90 Glass Microsphere in March 2021 for the treatment of patients with hepatocellular carcinoma.

Dr. Spira on the Role of Broad Molecular Testing in Lung Cancer

March 17th 2021

Alexander Spira, MD, PhD, FACP, discusses the role of broad molecular testing in lung cancer.